Product Pipeline

RH Nanopharma has developed and continues to develop new formulations of salsalate:

  • Oral tablets, capsules, and soft gel caps of immediate release salsalate
  • Liquid formulation of immediate release salsalate
  • Nanosupsensions of salsalate for Intravenous use in reducing operative pain
  • Topical gels for soft tissue injury/pain using nanoparticles of salsalate
  • Ocular nanosuspensions for Dry Eye Disease (DED)
  • Nanosupension of oral salsalate for immediate relief of pain (first human trial Feb 2018)

Our Mission

RH/Nanopharma is a pharmaceutical research and development company dedicated to treating, preventing, slowing and reversing inflammatory diseases.

News and Events

RH Nanopharmacuticals Announces that U.S. FDA granted Pre-Investigational New Drug Meeting (Pre-IND) for Salsalate to be held on June 28, 2018